SAB Biotherapeutics, Inc. (SABS)
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- $13.3M
- Total assets
- $172.8M
- Market cap
- $258.4M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $49.0M
- Operating income
- -$49.0M
- Income tax
- $0
- Net income
- $13.3M
- EPS (basic)
- $0.22
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $172.8M
- Current assets
- $101.1M
- Total liabilities
- $21.3M
- Current liabilities
- $10.7M
- Shareholders’ equity
- $151.5M
Cash flow
- Operating cash flow
- -$44.8M
- Investing cash flow
- -$121.7M
- Financing cash flow
- $168.3M
- Net cash flow
- $1.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $258.4M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 73.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 22, 2021
SAB Biotherapeutics, Inc. (SABS) Stock Price
- Profitable — net income of $13.3M in FY2025.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SAB Biotherapeutics, Inc..
Write a review
News about SAB Biotherapeutics, Inc.
News & sentiment via Polygon.io
SAB Biotherapeutics, Inc.: frequently asked questions
Is SAB Biotherapeutics, Inc. an American company?
SAB Biotherapeutics, Inc. is a US-based company headquartered in Miami Beach, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc. is headquartered in Miami Beach, Florida, United States.
Is SAB Biotherapeutics, Inc. publicly traded?
Yes — SAB Biotherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol SABS on the NASDAQ.
What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
